Stockscreener 앱 받기
1.99
1.02%
0.02
시간 외 거래:
2.00
0.01
+0.50%
Palisade Bio Inc 주식(PALI)의 최신 뉴스
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients - Insider Monkey
PALI Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Day Trade: Can Palisade Bio Inc beat the S P 500Bear Alert & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (PALI) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio (PALI) Stock Analysis Report | Financials & Insights - Benzinga Japan
RSI Check: Will Palisade Bio Inc outperform its industry peers2026 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Macro: Can Palisade Bio Inc maintain sales growth2025 Buyback Activity & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-03-07 13:46:23 - baoquankhu1.vn
US Market Recap: Will Palisade Bio Inc stock recover after earningsTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Treasury Yields: Will Palisade Bio Inc benefit from current market trends2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Bitget
Investors get two chances to question Palisade Bio in March - Stock Titan
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference - MarketBeat
Palisade Bio (NASDAQ:PALI) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Palisade Bio (NASDAQ:PALI) Upgraded to “Hold” at Wall Street Zen - Defense World
PALI Should I Buy - Intellectia AI
PALI: Advancing a once-daily, gut-restricted PDE4 inhibitor with strong funding and pivotal trials ahead - TradingView
Palisade Bio (NASDAQ:PALI) Now Covered by Stifel Nicolaus - MarketBeat
Stifel Initiates Palisade Bio at Buy With $5 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palisade Bio (PALI) Sees New 'Buy' Rating from Stifel | PALI Sto - GuruFocus
Stifel Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - Nasdaq
Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS) - The Globe and Mail
Stifel initiates Palisade Bio stock with buy rating on IBD drug - Investing.com South Africa
PALI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stifel initiates Palisade Bio stock with buy rating on IBD drug By Investing.com - Investing.com Canada
Palisade Bio Strengthens Advisory Board, Fast-tracks Key Research Developments - timothysykes.com
Palisade Bio presents ulcerative colitis drug trial data at ECCO By Investing.com - Investing.com India
Palisade Bio presents ulcerative colitis drug trial data at ECCO - Investing.com
Palisade Bio, Inc. Presents Phase 1b Data Demonstrating Localized Target Engagement and Early Clinical Response of PALI-2108 in Ulcerative Colitis at ECCO 2026 - Quiver Quantitative
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 - Bitget
Palisade Bio Reports Rapid Clinical, Histologic and New - GlobeNewswire
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest - Defense World
Palisade Bio appoints IBD expert to clinical advisory board By Investing.com - Investing.com Canada
Perceptive fund discloses 9.99% Palisade Bio (PALI) ownership stake - Stock Titan
Palisade Bio appoints IBD expert to clinical advisory board - Investing.com
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - Bitget
Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Ulcerative colitis drug PALI-2108 gets boost from new IBD advisor - Stock Titan
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com UK
Can Palisade Bio Inc. (7NS0) stock resist broad market declinesPortfolio Risk Report & Precise Trade Entry Recommendations - mfd.ru
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com Australia
Palisade Bio CEO Finley sells $6818 in shares - Investing.com South Africa
Palisade Bio CEO Finley sells $6818 in shares By Investing.com - Investing.com India
1.20%
0.06%
자본화:
|
볼륨(24시간):